Themis Medicare Limited has informed the Exchange about press release dated 18-May-2022 titled Receipt of add on approval for our drug VIRALEX for the treatment of Influenza and other Acute Viral Respiratory Infections (AVRI), Mucocutaneous herpes, Genital wart and Subacute Sclerosing Panenceph